ÿþ<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:x="urn:schemas-microsoft-com:office:excel" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"> <head> <meta http-equiv=Content-Type content="text/html; charset=unicode"> <meta name=ProgId content=Word.Document> <meta name=Generator content="Microsoft Word 12"> <meta name=Originator content="Microsoft Word 12"> <link rel=File-List href="MedChemDrug.files/filelist.xml"> <link rel=Edit-Time-Data href="MedChemDrug.files/editdata.mso"> <!--[if !mso]> <style> v\:* {behavior:url(#default#VML);} o\:* {behavior:url(#default#VML);} w\:* {behavior:url(#default#VML);} .shape {behavior:url(#default#VML);} </style> <![endif]--> <link rel=themeData href="MedChemDrug.files/themedata.thmx"> <link rel=colorSchemeMapping href="MedChemDrug.files/colorschememapping.xml"> <!--[if gte mso 9]><xml> <w:WordDocument> <w:TrackMoves/> <w:TrackFormatting/> <w:ValidateAgainstSchemas/> <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid> <w:IgnoreMixedContent>false</w:IgnoreMixedContent> <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText> <w:DoNotPromoteQF/> <w:LidThemeOther>RU</w:LidThemeOther> <w:LidThemeAsian>X-NONE</w:LidThemeAsian> <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript> <w:Compatibility> <w:DoNotExpandShiftReturn/> <w:BreakWrappedTables/> <w:SplitPgBreakAndParaMark/> <w:DontVertAlignCellWithSp/> <w:DontBreakConstrainedForcedTables/> <w:DontVertAlignInTxbx/> <w:Word11KerningPairs/> <w:CachedColBalance/> </w:Compatibility> <w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel> <m:mathPr> <m:mathFont m:val="Cambria Math"/> <m:brkBin m:val="before"/> <m:brkBinSub m:val="&#45;-"/> <m:smallFrac m:val="off"/> <m:dispDef/> <m:lMargin m:val="0"/> <m:rMargin m:val="0"/> <m:defJc m:val="centerGroup"/> <m:wrapIndent m:val="1440"/> <m:intLim m:val="subSup"/> <m:naryLim m:val="undOvr"/> </m:mathPr></w:WordDocument> </xml><![endif]--><!--[if gte mso 9]><xml> <w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="true" DefSemiHidden="true" DefQFormat="false" DefPriority="99" LatentStyleCount="267"> <w:LsdException Locked="false" Priority="0" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Normal"/> <w:LsdException Locked="false" Priority="9" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="heading 1"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 2"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 3"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 4"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 5"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 6"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 7"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 8"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 9"/> <w:LsdException Locked="false" Priority="39" Name="toc 1"/> <w:LsdException Locked="false" Priority="39" Name="toc 2"/> <w:LsdException Locked="false" Priority="39" Name="toc 3"/> <w:LsdException Locked="false" Priority="39" Name="toc 4"/> <w:LsdException Locked="false" Priority="39" Name="toc 5"/> <w:LsdException Locked="false" Priority="39" Name="toc 6"/> <w:LsdException Locked="false" Priority="39" Name="toc 7"/> <w:LsdException Locked="false" Priority="39" Name="toc 8"/> <w:LsdException Locked="false" Priority="39" Name="toc 9"/> <w:LsdException Locked="false" Priority="35" QFormat="true" Name="caption"/> <w:LsdException Locked="false" Priority="10" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Title"/> <w:LsdException Locked="false" Priority="1" Name="Default Paragraph Font"/> <w:LsdException Locked="false" Priority="11" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Subtitle"/> <w:LsdException Locked="false" Priority="22" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Strong"/> <w:LsdException Locked="false" Priority="20" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Emphasis"/> <w:LsdException Locked="false" Priority="59" SemiHidden="false" UnhideWhenUsed="false" Name="Table Grid"/> <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Placeholder Text"/> <w:LsdException Locked="false" Priority="1" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="No Spacing"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 1"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 1"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 1"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 1"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 1"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 1"/> <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Revision"/> <w:LsdException Locked="false" Priority="34" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="List Paragraph"/> <w:LsdException Locked="false" Priority="29" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Quote"/> <w:LsdException Locked="false" Priority="30" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Intense Quote"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 1"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 1"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 1"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 1"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 1"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 1"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 1"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 1"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 2"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 2"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 2"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 2"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 2"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 2"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 2"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 2"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 2"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 2"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 2"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 2"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 2"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 2"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 3"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 3"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 3"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 3"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 3"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 3"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 3"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 3"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 3"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 3"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 3"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 3"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 3"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 3"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 4"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 4"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 4"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 4"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 4"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 4"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 4"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 4"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 4"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 4"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 4"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 4"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 4"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 4"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 5"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 5"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 5"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 5"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 5"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 5"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 5"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 5"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 5"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 5"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 5"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 5"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 5"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 5"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 6"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 6"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 6"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 6"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 6"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 6"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 6"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 6"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 6"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 6"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 6"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 6"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 6"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 6"/> <w:LsdException Locked="false" Priority="19" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Subtle Emphasis"/> <w:LsdException Locked="false" Priority="21" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Intense Emphasis"/> <w:LsdException Locked="false" Priority="31" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Subtle Reference"/> <w:LsdException Locked="false" Priority="32" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Intense Reference"/> <w:LsdException Locked="false" Priority="33" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Book Title"/> <w:LsdException Locked="false" Priority="37" Name="Bibliography"/> <w:LsdException Locked="false" Priority="39" QFormat="true" Name="TOC Heading"/> </w:LatentStyles> </xml><![endif]--> <style> <!-- /* Font Definitions */ @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:1; mso-generic-font-family:roman; mso-font-format:other; mso-font-pitch:variable; mso-font-signature:0 0 0 0 0 0;} @font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:204; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-520092929 1073786111 9 0 415 0;} @font-face {font-family:Tahoma; panose-1:2 11 6 4 3 5 4 4 2 4; mso-font-charset:204; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-520081665 -1073717157 41 0 66047 0;} /* Style Definitions */ p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin-top:6.0pt; margin-right:0cm; margin-bottom:0cm; margin-left:0cm; margin-bottom:.0001pt; line-height:115%; mso-pagination:widow-orphan; font-size:11.0pt; font-family:"Calibri","sans-serif"; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin;} a:link, span.MsoHyperlink {mso-style-noshow:yes; mso-style-priority:99; color:blue; text-decoration:underline; text-underline:single;} a:visited, span.MsoHyperlinkFollowed {mso-style-noshow:yes; mso-style-priority:99; color:purple; text-decoration:underline; text-underline:single;} p {mso-style-noshow:yes; mso-style-priority:99; mso-margin-top-alt:auto; margin-right:0cm; mso-margin-bottom-alt:auto; margin-left:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman","serif"; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin;} p.MsoAcetate, li.MsoAcetate, div.MsoAcetate {mso-style-noshow:yes; mso-style-priority:99; mso-style-link:""5:AB 2K=>A:8 =0:"; margin:0cm; margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:8.0pt; font-family:"Tahoma","sans-serif"; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin;} span.a {mso-style-name:""5:AB 2K=>A:8 =0:"; mso-style-noshow:yes; mso-style-priority:99; mso-style-unhide:no; mso-style-locked:yes; mso-style-link:""5:AB 2K=>A:8"; mso-ansi-font-size:8.0pt; mso-bidi-font-size:8.0pt; font-family:"Tahoma","sans-serif"; mso-ascii-font-family:Tahoma; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Tahoma; mso-bidi-font-family:Tahoma;} p.Tekstdymka, li.Tekstdymka, div.Tekstdymka {mso-style-name:"Tekst dymka"; mso-style-unhide:no; mso-style-link:"Tekst dymka Znak"; margin-top:6.0pt; margin-right:0cm; margin-bottom:0cm; margin-left:0cm; margin-bottom:.0001pt; line-height:115%; mso-pagination:widow-orphan; font-size:11.0pt; font-family:"Calibri","sans-serif"; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin;} span.TekstdymkaZnak {mso-style-name:"Tekst dymka Znak"; mso-style-priority:99; mso-style-unhide:no; mso-style-locked:yes; mso-style-link:"Tekst dymka"; font-family:"Tahoma","sans-serif"; mso-ascii-font-family:Tahoma; mso-hansi-font-family:Tahoma; mso-bidi-font-family:Tahoma;} span.EmailStyle22 {mso-style-type:personal; mso-style-noshow:yes; mso-style-unhide:no; font-family:"Calibri","sans-serif"; mso-ascii-font-family:Calibri; mso-hansi-font-family:Calibri; mso-bidi-font-family:Calibri; color:windowtext;} span.productdetail-authorsmain {mso-style-name:productdetail-authorsmain; mso-style-unhide:no;} span.productdetail-purchaseprice {mso-style-name:productdetail-purchaseprice; mso-style-unhide:no;} span.EmailStyle25 {mso-style-type:personal-reply; mso-style-noshow:yes; mso-style-unhide:no; mso-ansi-font-size:11.0pt; mso-bidi-font-size:11.0pt; font-family:"Calibri","sans-serif"; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; color:#1F497D; mso-themecolor:dark2;} .MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-size:10.0pt; mso-ansi-font-size:10.0pt; mso-bidi-font-size:10.0pt;} @page WordSection1 {size:612.0pt 792.0pt; margin:70.85pt 70.85pt 70.85pt 70.85pt; mso-header-margin:36.0pt; mso-footer-margin:36.0pt; mso-paper-source:0;} div.WordSection1 {page:WordSection1;} --> </style> <!--[if gte mso 10]> <style> /* Style Definitions */ table.MsoNormalTable {mso-style-name:"1KG=0O B01;8F0"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-qformat:yes; mso-style-parent:""; mso-padding-alt:0cm 5.4pt 0cm 5.4pt; mso-para-margin:0cm; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:10.0pt; font-family:"Times New Roman","serif";} </style> <![endif]--><!--[if gte mso 9]><xml> <o:shapedefaults v:ext="edit" spidmax="1026"/> </xml><![endif]--><!--[if gte mso 9]><xml> <o:shapelayout v:ext="edit"> <o:idmap v:ext="edit" data="1"/> </o:shapelayout></xml><![endif]--> </head> <body bgcolor=white lang=RU link=blue vlink=purple style='tab-interval:35.4pt'> <div class=WordSection1> <p class=MsoNormal style='mso-layout-grid-align:none;text-autospace:none'><span style='color:black'><o:p>&nbsp;</o:p></span></p> <p class=MsoNormal><o:p>&nbsp;</o:p></p> <div> <p class=MsoNormal style='margin-top:0cm;line-height:normal'><span lang=PL style='font-size:12.0pt;font-family:"Times New Roman","serif";mso-fareast-font-family: "Times New Roman";mso-ansi-language:PL'>&nbsp;<o:p></o:p></span></p> </div> <div> <p class=MsoNormal style='margin-top:0cm;line-height:normal'><span lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman","serif";mso-fareast-font-family: "Times New Roman";mso-ansi-language:EN-US'>An important publication from Wiley. This book was published in September 2010.</span><b><span lang=EN-US style='font-size:14.0pt;font-family:"Times New Roman","serif";mso-fareast-font-family: "Times New Roman";mso-ansi-language:EN-US'><o:p></o:p></span></b></p> </div> <p class=MsoNormal><b><span lang=EN-US style='font-size:14.0pt;line-height: 115%;mso-ansi-language:EN-US'>Burger's Medicinal Chemistry, Drug Discovery and Development, 7th Edition, 8 Volume Set</span></b><b><span lang=EN-US style='font-size:12.0pt;line-height:115%;mso-ansi-language:EN-US'><o:p></o:p></span></b></p> <p class=MsoNormal><span lang=PL style='font-size:12.0pt;line-height:115%; mso-ansi-language:PL'><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f"> <v:stroke joinstyle="miter"/> <v:formulas> <v:f eqn="if lineDrawn pixelLineWidth 0"/> <v:f eqn="sum @0 1 0"/> <v:f eqn="sum 0 0 @1"/> <v:f eqn="prod @2 1 2"/> <v:f eqn="prod @3 21600 pixelWidth"/> <v:f eqn="prod @3 21600 pixelHeight"/> <v:f eqn="sum @0 0 1"/> <v:f eqn="prod @6 1 2"/> <v:f eqn="prod @7 21600 pixelWidth"/> <v:f eqn="sum @8 21600 0"/> <v:f eqn="prod @7 21600 pixelHeight"/> <v:f eqn="sum @10 21600 0"/> </v:formulas> <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/> <o:lock v:ext="edit" aspectratio="t"/> </v:shapetype><v:shape id="Obraz_x0020_1" o:spid="_x0000_i1025" type="#_x0000_t75" alt="cid:image001.png@01CBA73E.CD7096F0" style='width:75pt;height:112.8pt'> <v:imagedata src="MedChemDrug.files/image001.png" o:href="cid:C73819FCF593472E8845028D34B3714F@sunny"/> </v:shape><![endif]--><![if !vml]><img width=100 height=150 src="MedChemDrug.files/image002.jpg" alt="cid:image001.png@01CBA73E.CD7096F0" v:shapes="Obraz_x0020_1"><![endif]></span><span lang=EN-US style='font-size: 12.0pt;line-height:115%;mso-ansi-language:EN-US'><o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm'><span class=productdetail-authorsmain><span lang=EN-US style='font-size:12.0pt; line-height:115%;mso-ansi-language:EN-US'>Donald J. Abraham, David P. Rotella</span></span><span lang=EN-US style='font-size:12.0pt;line-height:115%;mso-ansi-language:EN-US'><o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm'><span lang=EN-US style='font-size: 12.0pt;line-height:115%;mso-ansi-language:EN-US'>ISBN: 978-0-470-27815-4<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm'><span lang=EN-US style='font-size: 12.0pt;line-height:115%;mso-ansi-language:EN-US'>Hardcover<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm'><span lang=EN-US style='font-size: 12.0pt;line-height:115%;mso-ansi-language:EN-US'>6416 pages<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm'><span lang=EN-US style='font-size: 12.0pt;line-height:115%;mso-ansi-language:EN-US'>September 2010<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm'><span class=productdetail-purchaseprice><span lang=EN-US style='font-size:12.0pt; line-height:115%;mso-ansi-language:EN-US'>£1,400.00 <b>Introductory price valid until the end of January 2011 </b>(£1,567.00 thereafter)</span></span><span lang=EN-US style='mso-ansi-language:EN-US'><o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm'><span lang=EN-US style='font-size: 12.0pt;line-height:115%;mso-ansi-language:EN-US'><o:p>&nbsp;</o:p></span></p> <p class=MsoNormal style='margin-top:0cm;line-height:normal'><span lang=EN-US style='font-size:12.0pt;color:black;mso-ansi-language:EN-US'>" Medicinal chemistry provides medical researchers with knowledge about chemical structures and reactions, and reaction and biochemical mechanisms of therapeutic agents  essential for the development of new drugs and treatment regimens and understanding the molecular basis of disease <o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;line-height:normal'><span lang=EN-US style='font-size:12.0pt;color:black;mso-ansi-language:EN-US'>" An established, recognized, authoritative and comprehensive source on medicinal chemistry and drug discovery and development<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;line-height:normal'><span lang=EN-US style='font-size:12.0pt;color:black;mso-ansi-language:EN-US'>" Thoroughly updated and expanded to 8 volumes<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;line-height:normal'><span lang=EN-US style='font-size:12.0pt;color:black;mso-ansi-language:EN-US'>" Now incorporates the entire process of drug development (preclinical testing, clinical trials etc.) as well as medicinal chemistry and drug discovery<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;line-height:normal'><span lang=EN-US style='font-size:12.0pt;color:black;mso-ansi-language:EN-US'>" The only reference covering such breadth and depth<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;line-height:normal'><span lang=EN-US style='font-size:12.0pt;color:black;mso-ansi-language:EN-US'><o:p>&nbsp;</o:p></span></p> <p class=MsoNormal style='margin-top:0cm;line-height:normal'><b><span lang=EN-US style='font-size:12.0pt;color:#40F300;mso-ansi-language:EN-US'>Audience: </span></b><span lang=EN-US style='font-size:12.0pt;color:black;mso-ansi-language: EN-US'>Research Departments in industry, including Pharmaceutical, Biotechnology and Agricultural Companies, Biomedical Research Institutes, Medical, Pharmaceutical, and Veterinarian Schools, Libraries, and Consultants. Readers will range from Graduate Students to Professional Bioengineers, Biologists, Chemists, and Medical Researchers with an emphasis on Medicinal and Clinical Chemists.</span><span lang=EN-US style='font-size:12.0pt;mso-ansi-language: EN-US'><o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm'><span lang=EN-US style='font-size: 12.0pt;line-height:115%;mso-ansi-language:EN-US'><o:p>&nbsp;</o:p></span></p> <p class=MsoNormal style='margin-top:0cm;line-height:normal'><b><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Volume 1: Methods in Drug Discovery.</span></b><span lang=EN-US style='font-size:12.0pt; mso-ansi-language:EN-US'><o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>History of Quantitative Structure Activity Relationships.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Mass spectrometry and drug discovery.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Chirality and Biological Activity.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Analog design.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>SNPs: Single Nucleotide Polymorphisms and Pharmacogenomics - individually designed drug therapy.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Design of peptidomimetics.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Dual Acting Drugs.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Combinational chemistry and multiple parallel synthesis.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Allosteric proteins and drug discovery.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Principles of drug metabolism.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Pharmacophore-based drug design.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Use of biological fingerprints vs Structure/chemotypes to describe molecules.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Recent advances in development, validation and exploitation of QSAR models.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>The Application of recombinant DNA Technology in medicinal chemistry and drug discovery.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Structural genomics, its application in Chemistry, Biology, Medicine, and Drug Discovery.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;line-height:normal'><b><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Volume 2: Discovering Lead Molecules.</span></b><span lang=EN-US style='font-size:12.0pt; mso-ansi-language:EN-US'><o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Virtual screening.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Utility and applications of in vitro ADMET profiling in lead discovery.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Retrometabolism-Based Drug Design and Targeting.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Natural product screening.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Microbes to man; from the depths to drugs.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Multi-objective Optimization For Drug Discovery.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>GPCR homology model development and applications.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Structural Alerts for Toxicity.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Protein - Protein Interactions as Drug Discovery Targets.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>NMR-based Screening and Drug Discovery.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Membrane transport proteins and drug transport.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Receptor targets in drug discovery and development.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Selective Toxicities.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Chemogenomics - Systematization of Drug Discovery.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Docking and Scoring in Drug Discovery.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Recent Trends in Structure-Based Drug Design and Energetics.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>QM and QM/MM Approaches to Evaluating Binding Affinities.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Assessing the Bioavailability of Drug Delivery Systems: Mathematical Modeling.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Protein flexibility in in silico screening.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;line-height:normal'><b><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Volume 3: Drug Development.</span></b><span lang=EN-US style='font-size:12.0pt;mso-ansi-language: EN-US'><o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Large scale and scale up synthesis.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Physicochemical characterization and principles of oral dosage form selection.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>The FDA and drug regulatory issues.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Intellectual property in drug discovery and biotechnology.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Polymorphism and conjugation in drug delivery (crystal engineering).<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Prodrugs: Strategic Deployment, Metabolic Considerations and Chemical Design Principles.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Process Development of Protein Therapeutics.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Cost-Effectiveness Analyses throughout the Drug Development Life Cycle.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Provisional BCS Classification of the Leading Oral Drugs on the Global Market.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>The role of permeability in drug ADME/PK, interactions and toxicity, and the Permeability-based Classification System (PCS).<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Salt screening and selection.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Enzymatic assays for HTS or Assay Development for HTS.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Crystallographic Survey of the Endogenous Albumin Drug Transport System and its Application in Cancer Chemotherapy.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Nanotechnology in pharmaceuticals.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;line-height:normal'><b><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Volume 4: Cardiovascular, Endocrine and Metabolic Diseases.</span></b><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'><o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Diabetes Drugs and Emerging Targets.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>DPP-4 inhibitors.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Nuclear hormone receptor medicinal chemistry.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Thyroid hormones and thyromimetics.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Antihypertensives:renin inhibitors.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Antihypertensives - Angiotensin-converting enzyme inhibitors.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Atherosclerosis I: LDL Cholesterol Lowering.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Atherosclerosis I: HDL Elevation.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Anticoagulants.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Antiplatelets.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Congestive Heart Failure.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Endogenous vasoactive peptides.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Hematopoietic agents.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Oxygen delivery via allosteric effectors of hemoglobin and blood substitutes.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;line-height:normal'><b><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Volume 5: Pulmonary, Bone, Immunology, Vitamins and Autocoid Therapeutic Agents.</span></b><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'><o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Fundamentals of steroid chemistry and biochemistry.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Antiinflammatory Glucocorticoids.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Male sex hormones, analogs, and antagonists.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Female Sex Hormones (pick up from the online).<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Medicinal chemistry and therapeutic applications of the gaseotransmitters NO, CO and H2S and their prodrugs.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Retinoids.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Multiple sclerosis.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Ophthalmic agents.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Vitamins.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Drug Discovery in Non-Life Threatening Disorders: Erectile Dysfunction, Insomnia and Smoking Cessation.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Osteoporosis therapy: mechanistic antiresoptives.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Osteoporosis therapy: anabolics.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Current and Emerging Therapies in Chronic Obstructive Pulmonary Disease.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Agents acting on prostanoid &amp; TX receptors.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Therapeutic agents acting on RNA.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Immunosuppressive agents for the prevention of transplantation rejection.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;line-height:normal'><b><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Volume 6: Cancer.</span></b><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'><o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Natural product cytotoxics.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Histone Deacetylase Inhibitors: A brief overview of their role and medicinal chemistry.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Synthetic DNA-targeted chemotherapeutic agents and related tumor-activated prodrugs.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>PARP Inhibitors as Anticancer Agents.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Proteasome inhibitors.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>CNS Cancers.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Kinase inhibitors: Approved Drugs and Clinical Candidates.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Structure-Based Design of Kinase Inhibitors: Molecular Recognition of Protein Multiple Conformations.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Cancer drug resistance-targets and therapies.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>HSP inhibitors.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Gene therapy with plasmid DNA. <o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;line-height:normal'><b><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Volume 7: Antiinfectives.</span></b><span lang=EN-US style='font-size:12.0pt;mso-ansi-language: EN-US'><o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>The FDA Approved HIV-1 Protease Inhibitors for Treatment of HIV/AIDS.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>HIV integrase.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>CCR5 Antagonists.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Reverse Transcriptase Inhibitors (RTIs).<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Anti HCV agents.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Anti-DNA Virus Agents.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>B-lactam antibiotics-include monobactams, b-lactamase inhibitors.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Tetracyclines, aminoglycoside, macrolide, and miscellaneous antibiotics.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Synthetic antibacterial agents.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Antiprotozoal/ Antiparasitic Agents.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Antimalarials.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Anti-tuberculosis.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;line-height:normal'><b><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Volume 8: CNS Disorders.</span></b><span lang=EN-US style='font-size:12.0pt;mso-ansi-language: EN-US'><o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Chemical Perspective on Neurotransmission and Drug Discovery for the Central Nervous System.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Cognition.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Cholinergics/anticholinergics/muscarinics/nicotinics.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>CNS stimulants.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Anticonvulsants.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Antipsychotic agents.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Antidepressants.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Therapeutic Agents for the Treatment of Migraine.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Approaches to Amyloid Therapies for the Treatment of Alzheimers Disease.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Non-Amyloid Approaches to Alzheimer's Disease.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Stroke.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Therapeutic and Diagnostic Agents for Parkinson?s Disease.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>Opioid Receptor Ligands.<o:p></o:p></span></p> <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'>PET and SPECT in Drug Development.<o:p></o:p></span></p> <p class=MsoNormal><span lang=EN-US style='font-size:12.0pt;line-height:115%; mso-ansi-language:EN-US'><o:p>&nbsp;</o:p></span></p> </div> </body> </html>